SR
Sartorius Stedim Biotech S.A.
SRTOY · OTC
$23.57 +2.12% (+$0.49)
1M +2.81%
Market Cap 198.1B €
P/E Ratio 694.89x
Div. Yield 0.35%
ROE 6.92%
Bulios Fair Price
$13.5
42.7% downside
Current Price
$23.57
Undervalued Fair Value Overvalued
According to Bulios Fair Price, SRTOY is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Strong
7/9Valuation
0 /100
Expensive EV/EBITDA 137.76x
P/S 65.57x
P/B 46.76x
Growth
10 /100
Declining Rev. growth 6.55%
FCF growth 8.40%
Book val. growth 18.63%
Profitability
69 /100
Strong Net margin 9.44%
Op. margin 18.60%
FCF margin 8.03%
Quality
31 /100
Poor ROE 6.92%
ROA 3.60%
Asset turnover 0.38x
Debt
70 /100
Low Current ratio 1.16x
Int. coverage 6.28x
Net debt/EBITDA 1.51x
Stability
83 /100
Stable Rev. volatility 12.69%
EPS volatility 19.29%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about SRTOY
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
Rene Faber
Employees
10,265
Headquarters
Aubagne